HAEM4:Precursor Lymphoid Neoplasms

Primary Author(s)*

Put your text here

test

Graphical Data Links

Put your graphics here

General Disease Overview / Description of Cancer Category

Put your text here

WHO Classification Pages (Includes Links to Content)

• B-Lymphoblastic Leukemia/Lymphoma (B-ALL) with Recurrent Genetic Abnormalities

  - B-ALL with t(9;22)(q34.1;q11.2); BCR-ABL1
  - B-ALL with t(v;11q23.3); KMT2A-Rearranged
  - B-ALL with t(12;21)(p13.2;q22.1); ETV6-RUNX1
  - B-ALL with Hyperdiploidy
  - B-ALL with Hypodiploidy
  - B-ALL with t(5;14)(q31.1;q32.1); IGH/IL3
  - B-ALL with t(1;19)(q23;p13.3); TCF3-PBX1
  - B-ALL, BCR-ABL1-Like
  - B-ALL with iAMP21
  - B-ALL, Not Otherwise Specified

• T-Lymphoblastic Leukemia/Lymphoma (T-ALL)

  - HAEM5:Early T-precursor lymphoblastic leukaemia / lymphoma
  - HAEM4:NK-Lymphoblastic Leukemia/Lymphoma

Other Related Pages (Includes Links to Content)

• HAEM4:B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4
• HAEM4:B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6
• HAEM4:B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
• HAEM4:B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions
• HAEM4:B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements
• HAEM4:B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19)
• HAEM4:T-ALL/MEF2C
• HAEM4:T-cell lymphoblastic leukemia with t(7;14)(p15;q32)

Additional Information

Put your text here

References

EXAMPLE Book

1. Arber DA, et al., (2008). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, Editors. IARC Press: Lyon, France, p117-118.

Notes

*Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.